Cardiovascular Systems Inc (NASDAQ:CSII) has been assigned an average rating of “Hold” from the ten brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $41.67.
Several brokerages recently issued reports on CSII. Needham & Company LLC reissued a “hold” rating on shares of Cardiovascular Systems in a research note on Wednesday, October 31st. BidaskClub cut Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Saturday, September 22nd. Zacks Investment Research cut Cardiovascular Systems from a “hold” rating to a “strong sell” rating in a report on Wednesday, September 12th. Stifel Nicolaus began coverage on Cardiovascular Systems in a report on Wednesday, August 22nd. They set a “buy” rating and a $45.00 price target for the company. Finally, Lake Street Capital restated a “buy” rating and set a $50.00 price target on shares of Cardiovascular Systems in a report on Wednesday, August 1st.
CSII traded up $1.45 on Thursday, hitting $32.56. 19,618 shares of the company’s stock traded hands, compared to its average volume of 347,416. The company has a market capitalization of $1.06 billion, a PE ratio of 636.30 and a beta of 2.36. Cardiovascular Systems has a one year low of $20.58 and a one year high of $40.00. The company has a current ratio of 4.47, a quick ratio of 4.03 and a debt-to-equity ratio of 0.16.
Cardiovascular Systems (NASDAQ:CSII) last issued its earnings results on Tuesday, October 30th. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The business had revenue of $56.27 million for the quarter, compared to the consensus estimate of $55.96 million. Cardiovascular Systems had a net margin of 0.36% and a return on equity of 0.62%. Equities research analysts predict that Cardiovascular Systems will post -0.09 earnings per share for the current year.
In other news, CEO Scott R. Ward purchased 2,500 shares of the business’s stock in a transaction on Wednesday, August 29th. The stock was acquired at an average price of $38.39 per share, for a total transaction of $95,975.00. Following the acquisition, the chief executive officer now directly owns 278,362 shares of the company’s stock, valued at approximately $10,686,317.18. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Martha Goldberg Aronson purchased 3,000 shares of the business’s stock in a transaction on Thursday, November 1st. The shares were purchased at an average price of $28.72 per share, with a total value of $86,160.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at $86,160. The disclosure for this purchase can be found here. Insiders have sold a total of 3,177 shares of company stock valued at $119,274 in the last 90 days. 2.80% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. Lisanti Capital Growth LLC purchased a new position in shares of Cardiovascular Systems in the 3rd quarter worth approximately $1,204,000. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Cardiovascular Systems by 159.9% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 37,575 shares of the medical device company’s stock worth $1,471,000 after purchasing an additional 23,120 shares during the period. American Century Companies Inc. purchased a new position in shares of Cardiovascular Systems in the 3rd quarter worth approximately $2,721,000. Wells Fargo & Company MN boosted its holdings in shares of Cardiovascular Systems by 7.0% in the 3rd quarter. Wells Fargo & Company MN now owns 52,045 shares of the medical device company’s stock worth $2,037,000 after purchasing an additional 3,406 shares during the period. Finally, Comerica Bank purchased a new position in shares of Cardiovascular Systems in the 3rd quarter worth approximately $846,000. Hedge funds and other institutional investors own 79.58% of the company’s stock.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Featured Article: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.